Physician profile
Daniel E Edquist
NPI 1295723542
$2,770.85
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $56.79 · 2021: $274 · 2022: $761 · 2023: $993 · 2024: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $453.80 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.00 | 2020-2024 | Jardiance, Tradjenta, Spiriva Respimat |
| Glaxosmithkline, LLC. | $162.79 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $162.49 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $152.39 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.21 | 2022-2023 | |
| Lilly USA, LLC | $144.78 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.35 | 2022-2024 | Caplyta |
| Boston Scientific Corporation | $130.57 | 2021-2023 | Watchman Access System |
| Biohaven Pharmaceutical Holding Company Ltd. | $122.07 | 2022 | |
| Astellas Pharma US INC | $106.12 | 2022-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $80.66 | 2023-2024 | Gemtesa |
| Amgen INC. | $69.87 | 2022-2024 | Prolia, Evenity |
| Dexcom, INC. | $58.62 | 2022-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $52.15 | 2023 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $50.56 | 2023-2024 | Rexulti |
| Mylan Specialty L.P. | $50.39 | 2023-2024 | Yupelri |
| Idorsia Pharmaceuticals US INC | $43.11 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $38.64 | 2022-2024 | Spravato |
| Astrazeneca Pharmaceuticals Lp | $38.38 | 2019-2024 | |
| Allergan, INC. | $34.22 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $32.67 | 2021 | |
| Merck Sharp & Dohme LLC | $32.34 | 2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Nevro Corp. | $31.84 | 2023 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $31.65 | 2021 | |
| Lundbeck LLC | $28.24 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $25.94 | 2024 | Auvelity |
| Esperion Therapeutics, INC. | $25.37 | 2021 | |
| Eisai INC. | $24.80 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $24.00 | 2023 | |
| Phathom Pharmaceuticals, INC. | $18.71 | 2024 | Voquezna |
| Abbvie INC. | $15.83 | 2023 | Vraylar |
| Amarin Pharma, INC. | $14.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.97 | 2020 | |
| Sanofi Pasteur INC. | $13.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Edquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.